Profhilo® announces the launch of Profhilo® Structura this month, an advanced injectable treatment designed to specifically target and regenerate superficial facial fat in the midface.
Launching to the industry on 4th June in London, the European debut of Profhilo® Structura comes nearly a decade after UK and Ireland distributor HA-Derma unveiled Profhilo, the eponymous hyaluronic acid bioremodeling treatment.
Developed by IBSA using the patented NAHYCO® technology, Profhilo® Structura represents a notable breakthrough in aesthetic medicine. It is the first injectable treatment specifically designed for adipose tissue restoration, clinically proven to help reposition superficial fat to its natural state. This addresses critical age-related concerns including pronounced facial hollows, skin laxity, and altered facial contours resulting from midface fat loss.
Profhilo® Structura is injected in the preauricular area using a protocol that evaluates facial structure, including midface projection, hollows, laxity, and skin density. The treatment involves two sessions, typically one month apart, with minimal downtime, allowing patients to continue their daily activities immediately post-treatment.
Clinical trials of Profhilo® Structura have shown impressive outcomes. 95% of patients noticed lasting enhancements in the mid-face area after the first treatment, with this improvement sustained three months later.
'Profhilo® is a trusted leader in aesthetic medicine,' says Iveta Vinkler, Sales and Marketing Director at HA-Derma. 'While fat often carries negative connotations, it's actually a crucial marker of youth. Our insights into its role in youthful aesthetics are advancing rapidly. The launch of Profhilo® Structura equips medical professionals with a natural product tailored to meet the evolving demands of today's discerning aesthetic clients.'
Profhilo Structura training will be available from HA-Derma and Harley Academy from July.